104 related articles for article (PubMed ID: 12898363)
21. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
22. [Gastrointestinal stromal tumors (GIST)].
Reichardt P; Pink D; Mrozek A; Lindner T; Hohenberger P
Z Gastroenterol; 2004 Apr; 42(4):327-31. PubMed ID: 15095124
[TBL] [Abstract][Full Text] [Related]
23. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
[TBL] [Abstract][Full Text] [Related]
24. [Gastrointestinal stromal tumor].
Nishida T; Ohmori T; Matsuda H
Gan To Kagaku Ryoho; 2004 Mar; 31(3):331-6. PubMed ID: 15045935
[TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal stromal tumors (GISTs): a pathology view point.
Sornmayura P
J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
[TBL] [Abstract][Full Text] [Related]
26. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
Sawaki A; Yamao K
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal stromal tumours.
Connolly EM; Gaffney E; Reynolds JV
Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
30. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
[TBL] [Abstract][Full Text] [Related]
31. [New oncological treatment principle with imatinib].
Kuenen BC; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2044-5. PubMed ID: 14606348
[TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal stromal tumors: a contemporary review.
Parfitt JR; Streutker CJ; Riddell RH; Driman DK
Pathol Res Pract; 2006; 202(12):837-47. PubMed ID: 17064855
[TBL] [Abstract][Full Text] [Related]
33. [Imatinib--a new perspective in the treatment of tumors].
Klener P; Klamová H
Cas Lek Cesk; 2004; 143(9):579-80, 582-3. PubMed ID: 15532894
[TBL] [Abstract][Full Text] [Related]
34. [Metastatic gastrointestinal stromal tumors responded to the treatment with STI571 after polysurgery for recurrent lesions--report of two cases].
Sasaki K; Doi T; Matsumoto G; Tsuruta K; Okamoto A; Funada N
Gan To Kagaku Ryoho; 2003 Jul; 30(7):1021-5. PubMed ID: 12894723
[TBL] [Abstract][Full Text] [Related]
35. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK
Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563
[TBL] [Abstract][Full Text] [Related]
36. Gastrointestinal stromal tumor.
Gupta P; Tewari M; Shukla HS
Surg Oncol; 2008 Aug; 17(2):129-38. PubMed ID: 18234489
[TBL] [Abstract][Full Text] [Related]
37. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
38. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
Renouf DJ; Wilson L; Blanke CD
Clin Cancer Res; 2009 Jun; 15(12):3908-11. PubMed ID: 19509180
[TBL] [Abstract][Full Text] [Related]
39. [Imatinib and solid tumours].
Arifi S; El Sayadi H; Dufresne A; Ray-Coquard I; Fayette J; Méeus P; Ranchère D; Decouvelaere AV; Alberti L; Tabone-Eglinger S; Blay JY; Cassier P
Bull Cancer; 2008 Jan; 95(1):99-106. PubMed ID: 18230575
[TBL] [Abstract][Full Text] [Related]
40. [Two cases of postoperative recurrence of gastric GIST treated by imatinib].
Kikuchi H; Konn H; Kamiya K; Baba M; Ohta M; Kondo K; Hiramatsu Y; Yamamoto M; Tanaka T; Sugimura H; Ohashi M; Kanda T; Nakamura S
Gan To Kagaku Ryoho; 2004 Oct; 31(10):1569-73. PubMed ID: 15508453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]